It is easy to talk about due diligence in the abstract, but it is much harder to practice what you preach. One of the hardest things about early stage investing is that it is really risky – if you don’t have some suspension of disbelief, and you obsess too much about cataloging every risk, you will never get a deal done. As a way of wrapping up this series of articles with a review, let’s take a look at a few common mistakes and see what we can learn from them.
- Delta Development Team Equips Kenosha WI EMS Carry Blood to the Frontline
- NuvOx Announces Positive Results 1st Cohort Phase Ib Trial
- Tech Parks Arizona Economic Impact
- Delta Development Team Exceeds New Prehospital Blood Transfusion Standards
- Clinical Trial Confirms GammaTile Superior Tumor Control
- 2025 Brutal Biotech Investment Climate
- Delta Development Team – Introducing BloodCOMM Premium
- Special Operations Forces Blood Cooler from Delta Development
- UACI startup alumni Reglagene making impressive strides in brain cancer treatment
- Reglagene RGN6024 Cover Story August 2025 Molecular Cancer Therapeutics